After the initial androgen deprivation therapy (ADT), part of the prostate cancer may
continuously deteriorate into castration-resistant prostate cancer (CRPC). The majority of …

Androgen receptor (AR) plays a vital role in prostate cancer (PCa), including castration-
resistant PCa, by retaining AR signalling. Androgen deprivation treatment (ADT) has been …

Since prostate cancer (PCa) was described as androgen-dependent, the androgen receptor
(AR) has become the mainstay of its systemic treatment: androgen deprivation therapy …

Prostate cancer (PCa) is a major diagnosed cancer among men globally, and about 20% of
patients develop metastatic prostate cancer (mPCa) in the initial diagnosis. PCa is a typical …

Androgens play a critical role in the progression of castration-resistant prostate cancer
through androgen receptor (AR)-regulated signaling pathways. Progress has been made in …

Androgen receptor (AR) signaling is a critical pathway for prostate cancer cells, and
androgen-deprivation therapy (ADT) remains the principal treatment for patients with locally …

The androgen receptor (AR) is a nuclear transcription factor that is essential for growth,
survival and proliferation of prostate cells. 1 AR also plays a key role in the initiation and …

Prostate cancer is a major health issue in western countries and is the second leading
cause of cancer death in American men. Prostate cancer depends on the androgen receptor …

The androgen signaling axis has been the main therapeutic target in the management of
advanced prostate cancer for several decades. Over the past years, significant advances …

Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …